Compare AbCellera Biologics Inc (ABCL) vs Waste Management, Inc. (WM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbCellera Biologics Inc vs Waste Management, Inc. — how do they compare? AbCellera Biologics Inc trades at $9.26 (market cap $2.99B), while Waste Management, Inc. trades at $226 (market cap $90.68B). The key difference: Waste Management, Inc. is far larger — about 30.3× AbCellera Biologics Inc's market cap, and Waste Management, Inc. pays a 1.56% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | WM | |
|---|---|---|
Market Cap | $2.99B | $90.68B |
Sector | Health | Industrials |
52-Week High | $9.76 | $246.51 |
52-Week Low | $2.78 | $196.77 |
Enterprise Value | $2.58B | $113.47B |
Dividend Yield | — | 1.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) surged 34.78% to $9.34, driven by positive Phase 2 trial results for its menopause drug ABCL635. Despite negative net income margins and cash burn, analyst consensus is strongly bullish with a $15.50 price target. The stock shows a bullish technical trend, with support at $8 and resistance at $10, though RSI levels indicate overbought conditions.
The outlook hinges on ABCL635's clinical progress and future revenue potential, but high valuation ratios and persistent losses pose significant risks. Investor sentiment is optimistic due to recent drug trial success, yet the company must demonstrate a path to profitability to justify current market enthusiasm.
WM trades at $226.6, down 0.47% over 24 hours, with a bullish technical signal and support near $226. The stock shows strong profitability with a 40.6% gross margin and 11.12% net margin, though its P/E of 59.74 is elevated. Recent Q2 2026 earnings beat expectations at $2.02 per share, and analyst consensus is a buy with a $263.43 price target. Cash flow from operations grew to $6.04B in 2025, but net cash flow was negative $190M due to investments.
Outlook is positive with revenue growth and margin stability, but risks include high valuation and debt levels. The stock offers upside to the consensus target, supported by institutional confidence and consistent earnings beats, though investors should monitor volume trends and interest rate impacts on borrowing costs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Waste Management, Inc.
Waste Management ranks as the largest integrated provider of traditional solid waste services in the United States, operating approximately 260 active landfills and about 340 transfer stations. The company serves residential, commercial, and industrial end markets and is also a leading recycler in North America.
Read more on WM →
